Frontier Biotechnologies(SH:688221) Zhong Guo Jing Ji Wang·2025-09-04 08:05Core Viewpoint - Frontier Biotech (688221.SH) reported a revenue of 58.64 million yuan for the first half of 2025, marking a year-on-year increase of 14.85%, but recorded a net loss attributable to shareholders of 97.35 million yuan, an improvement from a loss of 160 million yuan in the same period last year [1] Financial Performance - The company achieved a net cash flow from operating activities of -98.23 million yuan, compared to -89.19 million yuan in the previous year [1] - From 2018 to 2024, the net profit attributable to shareholders was -247 million yuan, -192 million yuan, -231 million yuan, -260 million yuan, -357 million yuan, -329 million yuan, and -201 million yuan respectively [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the same period was -167 million yuan, -202 million yuan, -240 million yuan, -311 million yuan, -399 million yuan, -355 million yuan, and -327 million yuan respectively [1] Initial Public Offering (IPO) Details - Frontier Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares at a price of 20.50 yuan per share [1] - The total amount raised from the IPO was 184.42 million yuan, with a net amount of 171.73 million yuan after expenses [2] - The company planned to use the raised funds for various projects, including the clinical development of HIV fusion inhibitors and pain relief patches, as well as for marketing network construction and working capital [2] Subsequent Fundraising - On September 22, 2022, the company issued 14.82 million shares at a price of 13.51 yuan per share, raising a total of approximately 200.20 million yuan, with a net amount of about 195.67 million yuan after deducting issuance costs [3] - The total fundraising from both IPOs amounted to approximately 2.04 billion yuan [4] Ownership Structure - The actual controller of Frontier Biotech is Dong Xie, who holds American nationality and has permanent residency in China [5]